Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(66.7%)

Phase 3

1(33.3%)

3Total

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06808412Phase 2Recruiting

To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer

Role: lead

NCT06680362Active Not Recruiting

The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery

Role: lead

NCT06681298Phase 2Active Not Recruiting

A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

Role: lead

NCT06411171Phase 3Not Yet Recruiting

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Role: lead

All 4 trials loaded